FerroKin BioSciences Announces Start of a Phase 2 Clinical Trial of FBS0701 as a Novel Oral Treatment for Transfusional Iron Overload in a Pediatric Population
September 19, 2011 12:49 ET
|
FerroKin BioSciences, Inc.
SAN FRANCISCO, Sept. 19, 2011 (GLOBE NEWSWIRE) -- FerroKin BioSciences today announced that the first dose has been administered in an international Phase 2 study of FBS0701, a novel once-daily oral...